Akebia Therapeutics (AKBA) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole?

Akebia Therapeutics (AKBA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

A multiple myeloma diagnosis in 2017 significantly altered travel dynamics, necessitating adaptations like wheelchair-accessible transport. Despite health challenges, the spirit of adventure persists, ...

Learn how to extract specific data from Excel cells using formulas, tools, and techniques to clean and organize messy datasets.

Affiliate Content. Discover the best joint supplements of 2025 in our expert-reviewed guide, designed to help you find effective, research-backed formulas that support mobility, reduce discomfort ...

A breakthrough in cancer treatment in the Valley: CARVYKTI therapy is helping Arizonans with multiple myeloma live longer, healthier lives.